Therapeutic targets in neonatal pulmonary hypertension: linking pathophysiology to clinical medicine

References

• Walsh-Sukys MC, Tyson JE, Wright LL et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics105(1 Pt 1), 14–20 (2000).
   PubMed Web of Science ®Google Scholar
• Tulloh RM. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr. Respir. Rev.6(3), 174–180 (2005).
   PubMedGoogle Scholar
• Leibovitch L, Matok I, Paret G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs67(1), 57–73 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr. Pulmonol.38(1), 2–22 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC 3rd, Wynn RJ, Ryan RM. Characteristics of pulmonary hypertension in preterm neonates. J. Perinatol.27(4), 214–219 (2007).
   PubMed Web of Science ®Google Scholar
• Macchia A, Marchioli R, Marfisi R et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J.153(6), 1037–1047 (2007).
   PubMed Web of Science ®Google Scholar
• Hislop A. Developmental biology of the pulmonary circulation. Paediatr. Respir. Rev.6(1), 35–43 (2005).
   PubMedGoogle Scholar
• Hislop AA, Pierce CM. Growth of the vascular tree. Paediatr. Respir. Rev.1(4), 321–327 (2000).
   PubMedGoogle Scholar
• Ghanayem NS, Gordon JB. Modulation of pulmonary vasomotor tone in the fetus and neonate. Respir. Res.2(3), 139–144 (2001).
   PubMedGoogle Scholar
• Haworth SG. Pulmonary hypertension in the young. Heart88(6), 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• Geggel RL, Reid LM. The structural basis of PPHN. Clin. Perinatol.11(3), 525–549 (1984).
   PubMed Web of Science ®Google Scholar
• Michalsky MP, Arca MJ, Groenman F, Hammond S, Tibboel D, Caniano DA. Alveolar capillary dysplasia: a logical approach to a fatal disease. J. Pediatr. Surg.40(7), 1100–1105 (2005).
   PubMed Web of Science ®Google Scholar
• Gelband CH, Katovich MJ, Raizada MK. Current perspectives on the use of gene therapy for hypertension. Circ. Res.87(12), 1118–1122 (2000).
   PubMedGoogle Scholar
• van Haaften T, Thebaud B. Adult bone marrow-derived stem cells for the lung: implications for pediatric lung diseases. Pediatr. Res.59(4 Pt 2), R94–R99 (2006).
   Google Scholar
• Deprest J, Jani J, Gratacos E et al. Fetal intervention for congenital diaphragmatic hernia: the European experience. Semin. Perinatol.29(2), 94–103 (2005).
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin. Chest Med.22(3), 405–418 (2001).
   PubMed Web of Science ®Google Scholar
• Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit. Care Med.35(9), 2037–2050 (2007).
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation58(6), 1107–1122 (1978).
   PubMed Web of Science ®Google Scholar
• Jones PL, Cowan KN, Rabinovitch M. Tenascin-C. Proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am. J. Pathol.150(4), 1349–1360 (1997).
   PubMed Web of Science ®Google Scholar
• Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr. Pulmonol.39(6), 492–503 (2005).
   PubMed Web of Science ®Google Scholar
• Thebaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology91(4), 291–297 (2007).
   PubMed Web of Science ®Google Scholar
• Weir EK, Lopez-Barneo J, Buckler KJ, Archer SL. Acute oxygen-sensing mechanisms. N. Engl. J. Med.353(19), 2042–2055 (2005).
   PubMed Web of Science ®Google Scholar
• Abu-Osba YK, Galal O, Manasra K, Rejjal A. Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate. Arch. Dis. Child.67(1 Spec No), 31–35 (1992).
   PubMed Web of Science ®Google Scholar
• Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. Arch. Dis. Child. Fetal Neonatal Ed.72(3), F184–F187 (1995).
   PubMed Web of Science ®Google Scholar
• Villamor E, Perez-Vizcaino F, Ruiz T, Tamargo J, Moro M. In vitro effects of magnesium sulfate in isolated intrapulmonary and mesenteric arteries of piglets. Pediatr. Res.39(6), 1107–1112 (1996).
   PubMedGoogle Scholar
• Wu TJ, Teng RJ, Tsou KI. Persistent pulmonary hypertension of the newborn treated with magnesium sulfate in premature neonates. Pediatrics96(3 Pt 1), 472–474 (1995).
   PubMed Web of Science ®Google Scholar
• Patole SK, Finer NN. Experimental and clinical effects of magnesium infusion in the treatment of neonatal pulmonary hypertension. Magnes. Res.8(4), 373–388 (1995).
   PubMedGoogle Scholar
• Chandran S, Haqueb ME, Wickramasinghe HT, Wint Z. Use of magnesium sulphate in severe persistent pulmonary hypertension of the newborn. J. Trop. Pediatr.50(4), 219–223 (2004).
   PubMed Web of Science ®Google Scholar
• Daffa SH, Milaat WA. Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the neoborn. Saudi Med. J.23(10), 1266–1269 (2002).
   PubMed Web of Science ®Google Scholar
• Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst. Rev.3, CD005588 (2007).
   Google Scholar
• Barrington KJ, Ryan CA, Finer NN. Effects of magnesium sulfate in a newborn piglet meconium aspiration model. J. Perinatol.20(6), 373–378 (2000).
   PubMedGoogle Scholar
• Velvis H, Moore P, Heymann MA. Prostaglandin inhibition prevents the fall in pulmonary vascular resistance as a result of rhythmic distension of the lungs in fetal lambs. Pediatr. Res.30(1), 62–68 (1991).
   PubMedGoogle Scholar
• Geraci MW, Gao B, Shepherd DC et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J. Clin. Invest.103(11), 1509–1515 (1999).
   PubMed Web of Science ®Google Scholar
• Sood BG, Delaney-Black V, Glibetic M, Aranda JV, Chen X, Shankaran S. PGE2/TXB2 imbalance in neonatal hypoxemic respiratory failure. Acta Paediatr.96(5), 669–673 (2007).
   PubMedGoogle Scholar
• Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin. Chest Med.22(3), 529–537, (2001).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol.35(1), 176–182 (2000).
   PubMed Web of Science ®Google Scholar
• Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J. Med. Assoc. Thai.90(1), 167–170 (2007).
   PubMedGoogle Scholar
• De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as ‘rescue’ therapy for pulmonary hypertension of the neonate. Paediatr. Anaesth.17(4), 394–395 (2007).
   PubMed Web of Science ®Google Scholar
• Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiol. Young13(4), 361–363 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J. Pediatr.141(6), 830–832 (2002).
   PubMed Web of Science ®Google Scholar
• De Jaegere AP, van den Anker JN. Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. Eur. Respir. J.12(4), 932–934 (1998).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Krupnik E, Tenor H et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am. J. Respir. Crit. Care Med.164(9), 1694–1700 (2001).
   PubMed Web of Science ®Google Scholar
• Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn. Lancet340(8823), 819–820 (1992).
   PubMed Web of Science ®Google Scholar
• Murad F. Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N. Engl. J. Med.355(19), 2003–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature. Arterioscler. Thromb. Vasc. Biol.27(9), 1877–1885 (2007).
   PubMed Web of Science ®Google Scholar
• Clark RH, Kueser TJ, Walker MW et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N. Engl. J. Med.342(7), 469–474 (2000).
   PubMed Web of Science ®Google Scholar
• Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst. Rev.4, CD000399 (2006).
   PubMedGoogle Scholar
• Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am. J. Physiol. Lung Cell. Mol. Physiol.289(5), L798–L806 (2005).
   PubMed Web of Science ®Google Scholar
• Khoo JP, Zhao L, Alp NJ et al. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation111(16), 2126–2133 (2005).
   PubMed Web of Science ®Google Scholar
• Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr. Pulmonol.36(6), 529–535 (2003).
   PubMed Web of Science ®Google Scholar
• Saidy K, al-Alaiyan S. The use of l-arginine [correction of F-arginine] and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Indian J. Pediatr.68(2), 175–177 (2001).
   PubMedGoogle Scholar
• Konduri GG, Mital S. Adenosine and ATP cause nitric oxide-dependent pulmonary vasodilation in fetal lambs. Biol. Neonate78(3), 220–229 (2000).
   PubMedGoogle Scholar
• Lakshminrusimha S, Russell JA, Wedgwood S et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med.174(12), 1370–1377 (2006).
   PubMed Web of Science ®Google Scholar
• Maurice DH, Palmer D, Tilley DG et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol.64(3), 533–546 (2003).
   PubMed Web of Science ®Google Scholar
• Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, Clarke WR. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am. J. Respir. Crit. Care Med.158(1), 279–288 (1998).
   PubMed Web of Science ®Google Scholar
• Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br. J. Pharmacol.137(8), 1187–1194 (2002).
   PubMed Web of Science ®Google Scholar
• Wharton J, Strange JW, Moller GM et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med.172(1), 105–113 (2005).
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353(20), 2148–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics117(4), 1077–1083 (2006).
   PubMed Web of Science ®Google Scholar
• Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation105(20), 2398–2403 (2002).
   PubMed Web of Science ®Google Scholar
• Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology91(1), 307–310 (1999).
   PubMed Web of Science ®Google Scholar
• Kleinsasser A, Loeckinger A, Hoermann C et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am. J. Respir. Crit. Care Med.163(2), 339–343 (2001).
   PubMed Web of Science ®Google Scholar
• Haase E, Bigam DL, Cravetchi O, Cheung PY. Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets. Shock26(1), 99–106 (2006).
   PubMedGoogle Scholar
• Ghofrani HA, Voswinckel R, Reichenberger F et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol.44(7), 1488–1496 (2004).
   PubMed Web of Science ®Google Scholar
• Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am. J. Respir. Crit. Care Med.172(6), 750–756 (2005).
   PubMed Web of Science ®Google Scholar
• Luong C, Eaton F, Thebaud B. Antenatal sildenafil attenuates features of persistent pulmonary hypertension of the newborn (PPHN) in rats with congenital diaphragmatic hernia (CDH). Presented at: 2006 PAS Annual Meeting, San Francisco, CA, USA, April 29–May 2, 2006.
   Google Scholar
• Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst. Rev.3, CD005494 (2007).
   Google Scholar
• McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J. Crit. Care21(2), 217–222 (2006).
   PubMed Web of Science ®Google Scholar
• Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol. Neonate89(1), 1–5 (2006).
   PubMedGoogle Scholar
• Khazin V, Kaufman Y, Zabeeda D et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J. Cardiothorac. Vasc. Anesth.18(2), 156–159 (2004).
   PubMed Web of Science ®Google Scholar
• Lobato EB, Beaver T, Muehlschlegel J, Kirby DS, Klodell C, Sidi A. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br. J. Anaesth.96(3), 317–322 (2006).
   PubMedGoogle Scholar
• Hentschel T, Yin N, Riad A et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology106(1), 124–131 (2007).
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tajimi K, Moritsune O, Kobayashi K, Okada K. Effects of milrinone on pulmonary vasculature in normal dogs and in dogs with pulmonary hypertension. Crit. Care Med.19(1), 68–74 (1991).
   PubMedGoogle Scholar
• Buckley MS, Feldman JP. Nebulized milrinone use in a pulmonary hypertensive crisis. Pharmacotherapy27(12), 1763–1766 (2007).
   PubMedGoogle Scholar
• Rashid N, Morin FC 3rd, Swartz DD et al. Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation. Pediatr. Res.60(5), 624–629 (2006).
   PubMedGoogle Scholar
• Thelitz S, Oishi P, Sanchez LS et al. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. Pediatr. Crit. Care Med.5(3), 234–239 (2004).
   PubMedGoogle Scholar
• Buchan KW, Magnusson H, Rabe KF, Sumner MJ, Watts IS. Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46–2005. Eur. J. Pharmacol.260(2–3), 221–226 (1994).
   PubMed Web of Science ®Google Scholar
• Perreault T, Baribeau J. Characterization of endothelin receptors in newborn piglet lung. Am. J. Physiol.268(4 Pt 1), L607–L614 (1995).
   Google Scholar
• Ziegler JW, Ivy DD, Kinsella JP, Abman SH. The role of nitric oxide, endothelin, and prostaglandins in the transition of the pulmonary circulation. Clin. Perinatol.22(2), 387–403 (1995).
   PubMed Web of Science ®Google Scholar
• Perreault T, Coceani F. Endothelin in the perinatal circulation. Can. J. Physiol. Pharmacol.81(6), 644–653 (2003).
   PubMedGoogle Scholar
• Gosselin R, Gutkowska J, Baribeau J, Perreault T. Endothelin receptor changes in hypoxia-induced pulmonary hypertension in the newborn piglet. Am. J. Physiol.273(1 Pt 1), L72–L79 (1997).
   PubMed Web of Science ®Google Scholar
• Perreault T, Berkenbosch JW, Barrington KJ et al. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr. Res.50(3), 374–383 (2001).
   PubMedGoogle Scholar
• Okazaki T, Sharma HS, McCune SK, Tibboel D. Pulmonary vascular balance in congenital diaphragmatic hernia: enhanced endothelin-1 gene expression as a possible cause of pulmonary vasoconstriction. J. Pediatr. Surg.33(1), 81–84 (1998).
   PubMed Web of Science ®Google Scholar
• Rosenberg AA, Kennaugh J, Koppenhafer SL, Loomis M, Chatfield BA, Abman SH. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J. Pediatr.123(1), 109–114 (1993).
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet358(9288), 1119–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Primary pulmonary hypertension. N. Engl. J. Med.336(2), 111–117 (1997).
   PubMed Web of Science ®Google Scholar
• Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst. Rev.3, CD004434 (2006).
   Google Scholar
• Moffett BS, Chang AC. Future pharmacologic agents for treatment of heart failure in children. Pediatr. Cardiol.27(5), 533–551 (2006).
   PubMedGoogle Scholar
• Goissen C, Ghyselen L, Tourneux P et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur. J. Pediatr. DOI: 10.1007/s00431-007-0531-y (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Barst RJ, Langleben D, Badesch D et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol.47(10), 2049–2056 (2006).
   PubMed Web of Science ®Google Scholar
• Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc. Health Risk Manag.3(1), 11–22 (2007).
   PubMedGoogle Scholar
• Shehata SM, Tibboel D, Sharma HS, Mooi WJ. Impaired structural remodelling of pulmonary arteries in newborns with congenital diaphragmatic hernia: a histological study of 29 cases. J. Pathol.189(1), 112–118 (1999).
   PubMed Web of Science ®Google Scholar
• Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J. Pediatr.132(1), 40–47 (1998).
   PubMed Web of Science ®Google Scholar
• Khush KK, De Marco T, Vakharia KT et al. Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension. J. Card. Fail.12(7), 507–513 (2006).
   PubMedGoogle Scholar
• Zhao L, Hughes JM, Winter RJ. Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung. Am. Rev. Respir. Dis.146(5 Pt 1), 1198–1201 (1992).
   PubMedGoogle Scholar
• Mathew B, Russell J, Steinhorn R et al. B-type natriuretic peptide (BNP) system in an ovine model of persistent pulmonary hypertension of the newborn (PPHN). Presented at: 2006 PAS Annual Meeting, San Fransisco, CA, USA, 29–2 May, 2006.
   Google Scholar
• Reynolds EW, Ellington JG, Vranicar M, Bada HS. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics114(5), 1297–1304 (2004).
   PubMed Web of Science ®Google Scholar
• Investigators VMAC. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA287(12), 1531–1540 (2002).
   PubMedGoogle Scholar
• Reynolds EW, Conely ET, Vranicar M. Nesiritide for the treatment of pulmonary hypertension and cor pulmonale in an infant. Pediatr. Cardiol.28(3), 229–233 (2007).
   PubMedGoogle Scholar
• Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr. Crit. Care Med.6(5), 543–546 (2005).
   PubMedGoogle Scholar
• Jefferies JL, Denfield SW, Price JF et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr. Cardiol.27(4), 402–407 (2006).
   PubMedGoogle Scholar
• Jefferies JL, Price JF, Denfield SW et al. Safety and efficacy of nesiritide in pediatric heart failure. J. Card. Fail.13(7), 541–548 (2007).
   PubMed Web of Science ®Google Scholar
• El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch. Dis. Child. Fetal Neonatal Ed.92(4), F320–F324 (2007).
   Google Scholar
• Somlyo AP, Wu X, Walker LA, Somlyo AV. Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev. Physiol. Biochem. Pharmacol.134, 201–234 (1999).
   PubMedGoogle Scholar
• Ward JP, Knock GA, Snetkov VA, Aaronson PI. Protein kinases in vascular smooth muscle tone – role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Pharmacol. Ther.104(3), 207–231 (2004).
   PubMedGoogle Scholar
• de Caestecker M. Serotonin signaling in pulmonary hypertension. Circ. Res.98(10), 1229–1231 (2006).
   PubMedGoogle Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med.354(6), 579–587 (2006).
   PubMed Web of Science ®Google Scholar
• Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res.98(3), 322–334 (2006).
   PubMed Web of Science ®Google Scholar
• Parker TA, Roe G, Grover TR, Abman SH. Rho kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am. J. Physiol. Lung Cell. Mol. Physiol.291(5), L976–L982 (2006).
   PubMed Web of Science ®Google Scholar
• McMurtry IF, Bauer NR, Fagan KA, Nagaoka T, Gebb SA, Oka M. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv. Exp. Med. Biol.543, 127–137 (2003).
   PubMed Web of Science ®Google Scholar
• Xing XQ, Gan Y, Wu SJ, Chen P, Zhou R, Xiang XD. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension. Drug News Perspect.19(9), 517–522 (2006).
   PubMedGoogle Scholar
• Fukumoto Y, Matoba T, Ito A et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart91(3), 391–392 (2005).
   PubMed Web of Science ®Google Scholar
• Ishikura K, Yamada N, Ito M et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ. J.70(2), 174–178 (2006).
   PubMed Web of Science ®Google Scholar
• Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock28(1), 4–14 (2007).
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol.290(2), L209–L221 (2006).
   PubMed Web of Science ®Google Scholar
• Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am. J. Physiol. Lung Cell. Mol. Physiol.283(3), L555–L562 (2002).
   PubMed Web of Science ®Google Scholar
• Tang JR, Markham NE, Lin YJ et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am. J. Physiol. Lung Cell. Mol. Physiol.287(2), L344–L351 (2004).
   PubMed Web of Science ®Google Scholar
• Balasubramaniam V, Tang JR, Maxey A, Plopper CG, Abman SH. Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse. Am. J. Physiol. Lung Cell. Mol. Physiol.284(6), L964–L971 (2003).
   PubMed Web of Science ®Google Scholar
• Nadeau S, Baribeau J, Janvier A, Perreault T. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr. Res.58(2), 199–205 (2005).
   PubMed Web of Science ®Google Scholar
• Lassus P, Turanlahti M, Heikkila P et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am. J. Respir. Crit. Care Med.164(10 Pt 1), 1981–1987 (2001).
   PubMed Web of Science ®Google Scholar
• Shehata SM, Mooi WJ, Okazaki T, ElHBanna I, Sharma HS, Tibboel D. Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension. Thorax54(5), 427–431 (1999).
   PubMedGoogle Scholar
• Grover TR, Parker TA, Abman SH. Vascular endothelial growth factor improves pulmonary vascular reactivity and structure in an experimental model of chronic pulmonary hypertension in fetal sheep. Chest128(6 Suppl.), S614 (2005).
   Google Scholar
• Thebaud B, Ladha F, Michelakis ED et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation112(16), 2477–2486 (2005).
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI. Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir. Res.7, 128 (2006).
   PubMed Web of Science ®Google Scholar